Atlas Trials

Pembrolizumab + Idelalisib for Lung Cancer Study

Clinical trial NCT03257722 · TERMINATED

Trial details

NCT number
NCT03257722
Sponsor
Asha Nayak
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung CancerMetastasisRecurrence
Start date
2017-09-26
Primary completion
2020-08-15
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.